Explore the words cloud of the SupraCarrier project. It provides you a very rough idea of what is the project "SupraCarrier" about.
The following table provides information about the project.
TECHNISCHE UNIVERSITEIT EINDHOVEN
|Coordinator Country||Netherlands [NL]|
|Total cost||150˙000 €|
|EC max contribution||150˙000 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2017-02-01 to 2018-07-31|
Take a look of project's partnership.
|1||TECHNISCHE UNIVERSITEIT EINDHOVEN||NL (EINDHOVEN)||coordinator||150˙000.00|
In recent years, macroscale drug delivery systems have been designed and investigated to spatiotemporally control the release of various bioactive agents and drugs at specific locations in the body. Many of these macroscale drug delivery vehicles are based on hydrogels. Depending on the location of application, and the temporal release kinetics, these hydrogel drug carriers need to be adjusted to the need of the application. Many of the currently available hydrogel systems do not have the capacity to be totally tuned. These systems: a) display a substantial initial burst release of the drug resulting in high drug doses at the initial phase; b) are difficult to apply (surgical implantation is necessary for various systems, thereby limiting their potential of easy/convenient application); c) provide only limited opportunities for chemical adjustment of their composition to improve key material properties such as their release kinetics and/or degradation rate. SupraCarrier aims to address these unmet needs by developing an injectable, supramolecular ureido-pyrimidinone (UPy) based hydrogel (UPy-hydrogel) drug delivery system that allows for local and sustained drug release. The unique selling points of this UPy-hydrogel system are: a) its demonstrated sustained drug release profile in vitro (with no initial burst release); b) its injectability due to its unique physicochemical properties (that allow for the development of clinical strategies using minimally invasive procedures); and c) its chemical structure and supramolecular assembly behaviour which allows for easy modification of either the UPy-hydrogel carrier or the drug (resulting in a versatile drug delivery platform). With SupraCarrier we aim to a) validate the commercial feasibility of a UPy-hydrogel as a novel local drug delivery system for controlled (and sustained) drug release; b) prioritise the medical applications where this system can be used; and c) provide a proof of concept for using a UPy-hydrogel
|year||authors and title||journal||last update|
Maarten H. Bakker, Maxime Grillaud, Dan Jing Wu, Peter-Paul K. H. Fransen, Ignace H. de Hingh, Patricia Y. W. Dankers
Cholesterol Modification of an Anticancer Drug for Efficient Incorporation into a Supramolecular Hydrogel System
published pages: 1800007, ISSN: 1022-1336, DOI: 10.1002/marc.201800007
|Macromolecular Rapid Communications 39/17||2019-10-08|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "SUPRACARRIER" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "SUPRACARRIER" are provided by the European Opendata Portal: CORDIS opendata.
High throughput multiplexed trace-analyte screening for diagnostics applicationsRead More
Streamlined carbon dioxide conversion in ionic liquids – a platform strategy for modern carbonylation chemistryRead More
The Neurological Basis of the Magnetic SenseRead More